Healthcare juggernaut Johnson & Johnson (JNJ) will report its third-quarter results on Oct. 13, before the market opens. Ahead of that, Wall Street analysts expect a marginal increase in Q3 EPS to $2.82. The company has also surpassed EPS estimates in each of the trailing four quarters. We take a closer look at J&J at this juncture.